Supernus Pharmaceuticals Inc (SUPN)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.22 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.29 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.33 | 0.32 | 0.32 | 0.32 | 0.33 | 0.33 | 0.34 | 0.35 | 0.36 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 0.46 | 0.46 | 0.47 | 0.49 | 0.49 | 0.50 | 0.53 | 0.57 |
| Financial leverage ratio | 1.32 | 1.33 | 1.37 | 1.40 | 1.39 | 1.41 | 1.41 | 1.96 | 1.92 | 1.99 | 2.01 | 1.98 | 2.07 | 1.92 | 2.00 | 2.00 | 2.02 | 2.13 | 2.24 | 1.94 |
Supernus Pharmaceuticals Inc's solvency ratios show a positive trend over the years. The debt-to-assets ratio has decreased significantly from 0.29 in March 2020 to 0.00 by June 2022, indicating a stronger financial position with lower reliance on debt to finance its assets. Similarly, the debt-to-capital ratio and debt-to-equity ratio have also shown a consistent decline, reflecting a reduction in financial leverage and a healthier balance between debt and equity in the capital structure.
The financial leverage ratio, which measures the extent of debt used in the company's capital structure, initially fluctuated but eventually decreased from 2.24 in June 2020 to 1.32 by December 2024. This suggests that Supernus Pharmaceuticals has been gradually deleveraging and reducing its overall financial risk.
Overall, the solvency ratios of Supernus Pharmaceuticals Inc indicate an improving financial health and a more stable capital structure, which could enhance the company's ability to weather economic downturns and pursue future growth opportunities.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | — | — | — | — | 4,194.00 | 9.61 | 5.22 | 8.94 | 9.25 | 4.60 | 5.80 | 5.95 | 4.72 | 6.75 | 7.93 | 8.61 | 9.68 | 9.97 | 9.47 | 9.42 |
The interest coverage ratio measures a company's ability to meet its interest obligations on outstanding debt. A higher ratio indicates a stronger ability to cover interest expenses with operating profits.
Analyzing the interest coverage ratio of Supernus Pharmaceuticals Inc over the past few years, we observe fluctuating trends. The ratio stood relatively stable around 9.00 during the first three quarters of 2020 and then dipped slightly to around 8.00 in March 2021. However, the ratio started declining significantly from June 2021, dropping to around 5.00 by the end of September 2021. This continued into the fourth quarter of 2021, reaching 4.72.
There was a slight improvement in the first quarter of 2022, with the ratio increasing to 5.95, but it dropped again by the second quarter of 2022 to 5.80. The trend continued through the third quarter of 2022, falling to 4.60.
In the fourth quarter of 2022, there was a notable increase in the interest coverage ratio to 9.25, indicating a temporary improvement in the company's ability to cover interest expenses. However, this improvement did not sustain, as the ratio decreased to 8.94 in the first quarter of 2023 and further dropped to 5.22 by the end of June 2023.
A significant anomaly is noted in the interest coverage ratio for December 31, 2023, which reflects an extremely high value of 4,194.00. Such a sudden spike may indicate data irregularities or one-time occurrences affecting the denominator of the ratio.
Unfortunately, the data for the interest coverage ratio is missing from March 31, 2024, and beyond, hindering a complete analysis of the trend in recent periods. However, based on the available information, Supernus Pharmaceuticals Inc has experienced fluctuations in its ability to cover interest expenses, suggesting varying levels of financial stability and debt servicing capacity over the analyzed period. Further analysis and disclosure of financial information would be necessary to provide a more comprehensive evaluation of the company's financial health in the subsequent periods.